Postradiotherapy erectile dysfunction in patients with prostate cancer: prospective study of sildenafil treatment of 31 patients

ABSTRACT

Out of 35 patients, 31 assessable ones participated in this prospective study. Using a 25-point scale based on the International Index of Sexual Function, erectile dysfunction was assessed weekly; during this time, the patients received sildenafil 50 mg orally once a week for eight consecutive weeks. The response was defined as a score of 18 or more corresponding to at least one successful attempt at sexual intercourse per week. It was concluded that oral sildenafil is safe, well-tolerated and can reverse erectile dysfunction after radiotherapy in a substantial proportion of the prostate cancer patients